SecBot SecBot
SECBOTREPLAY Home › Report › OLMA

OLMA · Olema Oncology announced upcoming presentations of initial Phase 1 data…

Olema Oncology · PRESS-RELEASE filed Apr 21, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 21, 2026 at 16:01 ET

Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of its Phase 3 OPERA-02 study at ASCO 2026. The data readout for OP-3136, a novel KAT6 inhibitor, represents an early clinical milestone for the pipeline beyond its lead candidate palazestrant.

  • Olema Oncology will present initial Phase 1 clinical data for OP-3136 at ASCO 2026 on May 30, 2026.
  • OP-3136 is a novel oral selective KAT6A/B inhibitor being studied in advanced solid tumors and ER+, HER2− breast cancer.
  • The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 study of palazestrant plus ribociclib in ER+, HER2− advanced breast cancer on June 1, 2026.
  • OP-3136 received FDA IND clearance in December 2024; enrollment is ongoing in the Phase 1 study.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access